【摘要】 目的探讨替米沙坦与氯沙坦治疗原发性高血压的疗效及安全性。方法将122例原发性高血压患者随机分为替米沙坦治疗组62例与氯沙坦治疗组60例,两组疗程均为8w。治疗前与疗程结束时分别采用美国产DP5000A动态血压监测系统进行24h动态血压监测分析。结果两组治疗前与治疗后24h、白昼与夜间平均血压均显著降低(P<0.01);治疗后替米沙坦组24h和夜间平均血压下降较氯沙坦组更显著(P<0.01);两组降压谷/峰比率分别为80.5±7.4%和62.8±4.3%,差异有极显著性(P<0.01)。结论替米沙坦是一种强效、安全、耐受性好的治疗高血压的良药。更多还原

【Abstract】 Objective To explore the efficacy and safety of telmisartan vs.losartan in primary hypertension. Methods 122 patients with primary hypertension were randomly divided into group 1(n=62) and 2(n=60) for 8 weeks.24h dynamic pressure monitors were conducted using DP5000A Ambulatory blood pressure monitoring system made in U.S.A. before and after treatment respectively. Results Compared with pre-treatment or daytime, mean pressures within 24h after treatment or at night fell significantly of both 2 groups(P<0.01), those of research group fell more significantly than that of control group did(P<0.01). Ratios of depressurization vallecula/peak of the 2 groups were 80.5±7.4% and 62.8±4.3%,diffrence was more significant(P<0.01). Conclusion Telmisartan is a potent, safe and well-tolerated drug in hypertension.更多还原